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As aculturization and globalization continues, there is an urgent need to carefully record and delineate 
traditional pharmacopeias so that their true worth is understood and protected and any possible benefits related to 
their commercial development are equitably distributed.  In the past most of these endeavors resulted in a list of 
plants with their associated uses without providing further explanations as to the extent of this knowledge within the 
traditional group, or if this knowledge was known elsewhere.  This practice tended to generate the notion of finite 
exclusivity without providing proof that this was actually the case.  Moreover, since the talents and methods of those 
conducting these initial studies varied widely, little effort was made to provide adequate information on how selective 
processes and preferences as well as modes of collection, preparation and use were achieved.  Without these data, 
the potential of their clinical worth, bioreactive capacities or chemical compositions were often compromised.  This 
frequently led to expending much time, effort and treasure on a pharmacopeia’s evaluation without guidance on how 
these efforts could be optimized to achieve its best possible medicinal potential. This paper will review how types of 






 Before appropriate dereplications can be applied to a traditional pharmacopeia it is important to know how 
these data were acquired and by whom.  The worth of this information is dependant upon the expertise of not only 
those involved in the acquisition of the data but also those that examine its worth. Nowadays to corroborate and/or 
exploit the medicinal value of a traditional-based pharmacopeia it is important to utilize the talents of many expert 
scientists. Such endeavors should be viewed as a team effort, with data evolved by one type of investigator providing 
insights to others along the validation process. 
 In the past it was not unusual for medicinal plant inventories pertaining to a specific traditional pharmacopeia 
to be conducted by individuals who were limited in their expertise.  This often generated a list of plants and/or local 
names associated with some, but not necessarily all of their uses.  I have observed that depending on the extent of 
the study, this occasionally results in incomplete or erroneous information being recorded regarding the true nature of 
the malady or remedy or the correct identification of the plant itself.  In the latter instance, when accompanying plant 
vouchers were not provided, or inappropriately prepared without fruit and/or flowers, misidentifications could be made 
in a variety of ways. Sometimes this has meant depending on local names to guide determinations without 
understanding if one or more disparate taxa were associated with this epithet e.g., Akan designation of “tweapea” for 
Garcinia afzellii and G. epunctata  (Adu-tutu. et al 1979; Elvin-Lewis, 1980, Elvin-Lewis, 1982).   There was also a 
tendency to list plants for a use without citing when and how the plant was collected, what plant part might be used, 
how it might be stored and prepared, and if it was used alone, sequentially or in combination with other plants or other 
substances.  
 Also, without knowledge of the local language or medical terms that were locally applied or conventionally 
known, medical descriptors could be so vague as to refer to the incorrect disease syndrome, or eliminate particular 
details, which could have further aided in the diagnosis.  This is particularly true in cases of those with multiple 
etiologies.  For example, detailed descriptions of symptoms are frequently critical to an appropriate diagnosis and/or 
etiological identification of gastrointestinal, dermatological or pulmonary infections.  Thus, in one ethnopharmacology 
Amazonian study related to traditional treatments for viral diarrheas among the Kayapó of Brazil, information 
regarding the duration of the illness and the nature of the stools was considered trivial and not recorded.  These 
omissions were unfortunate since it is generally recognized in the medical community that a short acute illness is 
more likely to be viral in origin and the color and consistency of fecal excrement is often indicative of the cause of the 
problem at least at the level of whether or not it is bacterial or parasitic in nature. Appreciating these differences would 
have been useful in prioritizing the evaluations that were executed.  In spite of this exclusion, the authors did conduct 
sufficient chemical and ethnobotanical dereplications so they were able to determine that “most of the genera 
employed included species that contained classes of compounds relevant to antiviral activity, or are related to species  
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used by other peoples for viral diseases or gastrointestinal troubles” (Elisabethsky and Posey, 1994). Causes of 
pulmonary infections are particularly difficult to assess unless one understands the types of disease that are regionally 
recognized, if they are acute or chronic, seasonal or perennial, primarily affect one age group or another, or if any 
unique symptoms (nature of sputa, cough etc) are related to a certain condition.  Adding this type of information is 
particularly valuable when additional in vitro studies are used to evaluate their worth such as for certain bacterial 
infections like tuberculosis, viral infections like influenza, or parasitic infestations, which cause lung involvement.  
 Understanding the nature and epidemiology of diseases, which are prominent in the study area is useful in 
distinguishing what might be expected and what might be unusual.  This is true for numerous infectious diseases as it 
is or certain medical ailments with circumscribed regional distributions. For example, confusion of what is meant by a 
medical descriptor may relate to how it is interpreted by the translator or in translation from one language to another.  
For instance, an ethnomedical study in Polynesia described the treatment of “yellow fever” by Homalanthus nutans 
(Euphorbiaceae) (Cox, 1991).  Since this virus was unknown to the locality I questioned those familiar with the 
Samoan language and the study and asked them how the ailment had been described.  Apparently the descriptor 
meant “yellowing eyes” inferring that the patient had jaundice, possibly due to hepatitis B (HBV) which is endemic to 
the region. These made sense since additional studies indicated its prostratin was inhibitory against Human 
Immunodeficiency viruses (HIV) and these viruses and HBV both possess reverse transcriptases (RT) (Lewis and 
Elvin-Lewis, 2003).  Of note, many plant compounds can elicit this interesting cross sensitivity.  Also, during the time I 
was involved in conducting a medicinal plant inventory of an indigenous Amazonian tribe our translator referred to a 
skin rash as being small pox.  As an infectious disease microbiologist this did not seem logical to me since there was 
a lack of variola-scarring in the populace.  In questioning the informant regarding the symptoms being reported it was 
apparent that the individual was referring to measles (rubeola) that was known to occur in the region. 
 To treat certain diseases several disparate groups have utilized the “doctrine of signatures” to select certain 
of their medicinal plants according to their shape or color etc., with the notion that these indicators provide some sort  
of cosmic clue as to their usefulness.  While many of these signs have little value, one cannot totally disregard all of 
these interesting secondary selective criteria.  Perhaps the best example is its application in identifying plant parts 
useful in the treatment of hepatitis and jaundice.  For example, in studying Amazonian hepatitis remedies a significant 
number of those selected fell into this category (Elvin-Lewis et al., 2002). In these cases as well as in other 
pharmacopeias I have examined worldwide, identifiable efficacious yellow compounds such as antioxidant and 
antiviral flavonoids have often been associated with the yellow fruits, roots, flowers and/or barks found in these 
formulations. Another example related to leaf shape was the use of the Penobscot Amerindians of Mayapple 
(Podophyllum spp) to treat venereal warts (Condyloma acuminata). This plant has serrated and multi-lobed leaves, 
which are similar in shape to these anal lesions. In the latter instance, this led to the identification of its bioreactive 
podophyllotoxins and the semi-synthesis of the topisomerase inhibitors, teniposide and etoposide useful in the 
treatment of cancers such as leukemia, lymphomas, as well as brain and bladder cancers (Lewis and Elvin-Lewis, 
2003). 
 The quality of data that is acquired during the initial interviewing process is but one aspect to be considered.  
Pivotal to the process of understanding a traditional-based pharmacopeia is to determine the type of medicinal 
practices that are involved, and if the knowledge is widespread and practiced among members of a community or only 
known to circumscribed healers. These differences will depend upon the number of individuals that should be 
interviewed within a neighborhood or regionally so a realistic consensus of what is valued and by whom can be 
generated.  Within this context one must be mindful of the fact that there are numerous selective processes at play as 
to how these remedies are chosen including a variety of social parameters together with those preferences based on 
gender, tribe or religion.  The contents of these remedies and prescribed uses may be rigidly adhered to or vary even 
within family units. However, when significant data are garnered from both practitioners and/or users alike, these 
perceptions of value can be applied to affirm their merit.  This is particularly true when a large number of specific 
treatments are known for a specific condition and when there is a critical need to identify those of value to the health 
of a community or region.  Detailed studies associated with chewing-stick use in Ghana (Adu-tutu et al., 1979, Elvin-
Lewis et al., 1980) and Amazonian hepatitis remedies in Peru (Elvin-Lewis et al., 2002), called “ethnomedical 
focusing” provided insights into the worth of this type of effort. In both instances, favored species proved to have 
significant relevant bioreactivities when laboratory studies were conducted, clinical verifications made, and 
appropriate ethnobotanical and/or chemical dereplications were executed.  
 Access to secondary information was limited in the past since academic libraries and the like rarely had 
sufficient collections of published data, access to government reports, theses from other nearby institutions etc. to 
provide investigators with information about related and/or regional pharmacopeias.  Also, when published in local 
languages, these were limited to those with the necessary linguistic expertise. The process of retrieving prior 
information from written reports could be painstaking whenever these sources failed to have adequate indices to 
facilitate the process.  Similarly, only large herbaria were likely to have large enough collections to provide a 
comprehensive overview of the distribution of the taxa, or have specimens with labels indicating ethnomedical uses. 
Presently, because of the need to protect traditional knowledge as “know how”, it is likely that some recent collections 
will indicate that ethnomedical data has been redacted from the herbarium label but is available through access to a 
defensive database (Elvin-Lewis, 2006; Elvin-Lewis 2007a; Elvin-Lewis 2007b; Christian, 2009).    
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 Today, many of these past problems have been overcome through information being readily retrieved from a 
wide range of electronically-based databases in ethnobotany, botany, biomedicine, pharmacognosy, chemistry, and 
clinical medicine including the process of meta-analytical and relevant patent pending or patented items from national 
and global patent agencies.  Aside from these specialized and professional resources, the internet is replete with 
additional information (accurate or otherwise) on subjects pertaining to medicinal plants and their uses.  These 
dereplication processes are invaluable in revealing what is already known, and how studies should proceed to 
optimize the worth of a traditional pharmacopeia as well as being helpful in revealing new avenues for research that 




The issue of protecting traditional knowledge is an ongoing process as is evident by the ongoing draft 
revision of the WHO 1993 guidelines related to the conservation of medicinal plants, national and regional 
conferences on the subject, in addition to recent reports (Christian, 2009). Since the object of this paper is to provide 
ways in which pharmacopeias can be validated for their worth and/or commercial potential it is important that all future 
studies comply with these ethical guidelines and are sensitive to global, regional and national policies and laws which 
would impact on such endeavors.  Readers may also refer to discussions on how both collective (CK) and traditional 
knowledge (TK) are defined, how claims of ownership can vary and can be utilized if in the public domain, in addition 
to ways circumscribed TK might be protected through defensive databases, trade secrets, sui generis laws, and the 
“requirement” associated with TK-associated genetic resources (Elvin-Lewis 2006, Elvin-Lewis 2007a, 2007b). 
 
Ethnobotanical/Ethnomedical Dereplication  
 
 The challenges to utilizing a unified approach when addressing the complexities of ethnobotanical research 
and applying bioinformatics are continuing and have yet to be resolved.  However practical solutions are likely to 
emerge as information technologies evolve and become more user friendly (Thomas, 2003). 
Until a consensus evolves these tasks may be pain-staking because of the lack of standardization and the myriad of 
ways this information is available.  Nonetheless these efforts are worthwhile if the full value of a traditional 
pharmacopeia is to be realized. 
  Ethnobotanical/ Ethnomedical dereplications are useful in determining the derivation of a remedy, whether 
or not it is ethnically specific, if it has been introduced from elsewhere through migration of populations or otherwise, if 
the use of the remedy is widespread because of its popularity or the distribution of the species, if it is used alone or as 
a mixture, and if treatment criteria gives a clue as to its value.  This technique is also useful in identifying related 
species, when sourcing issues demand alternate supplies. An understanding how this might be achieved has already 
been addressed in detail (Elvin-Lewis 2005a, Elvin-Lewis, 2005b, Elvin-Lewis, 2010). To emphasize the value of this 
and related methodologies a number of aspects will be reiterated throughout this paper.  
 Applying this knowledge is essential to identifying those remedies worthy of additional study.  For example, 
in today’s evolving paradigm it is becoming evident that medicinal plants, already preselected by empirical methods, 
are more likely to elicit positive “hits” when screened for a particular bioreactivity than those studied from plant 
libraries representing random collections of local or regional floras.  This is particularly true if the assay methods are 
complementary to mechanisms associated with “targeted” diseases. 
 However, this was not always the case.  Up until the late 20th century both the U.S. National Cancer Institute 
(NCI) and Industry believed that mass screening of randomly collected plants was more likely to yield unique and 
interesting compounds, than when their ethnomedical uses were taken into consideration. Using this approach a small 
number (2-8%) of active compounds was isolated from 32,000 species of flowering plants screened worldwide 
between 1956-81(WHO, 1989). A shining example of this effort was the discovery of the complex anticancer 
molecule, paclitaxel (taxol) from the North American Yew, Taxus brevifolia .  However, retrospective ethnomedical 
dereplication conducted several years later indicated that indeed an ethnomedical linkage existed in that the First 
Nation Tsimshian of Northern British Columbia and Alaska had used T. brevifolia ‘s wood for the treatment of cancers 
(Moerman 1991).  Moreover, when alternative sources were needed to satisfy the growing need for paclitaxel, an 
examination of other species for this compound or precursor molecules was initiated. Among these was the 
Himalayan anticancer plant T. walachiana, cited in the Bower Manuscript written between 1893 and 1912.  It is 
noteworthy that in the early days of paclitaxel’s development this association was known to NCI but not considered 
relevant (Hartwell, 1967).  It was only when this species and the European yew, T. baccata was identified as the 
potential source of the precursor molecule, baccatin III, needed to produce the semi-synthetic analog docetaxel, that a 
better appreciation of the worth of ethnomedical knowledge began to evolve. (Lewis and Elvin-Lewis, 2003). 
 At this time a number of other studies were beginning to indicate that screening of medicinal plants, which 
had been essentially disbanded, was once again becoming a worthwhile endeavor. This was particularly true when 
collaborative efforts evolved between those still utilizing their pharmacopeias and expert scientists that were able to 
accurately evaluate their worth. Optimal correlative results clearly depended upon the specificity of the assays and 
clinical evaluations that were being applied.   
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 In one study involving the NCI, HIV Screening program, a significant number of hits (15-25%) was elicited 
when medicinal plants from Belize, Central America were evaluated.  Most of these contained bioreactive compounds 
with the ability to react with a number of target sites as is often the case with highly complex polyphenolics or 
flavonoids (Balick, 1990).  On the whole these types of compounds, while not considered to be pharmaceutically 
viable, have the potential to become useful phytopharmaceuticals. 
  Additional unpublished data generated in 1992 through collaboration with the NCI HIV screening 
laboratories and those of Dr. Walter Lewis and I also affirmed this observation. Crude extracts of 25 plant collections 
prescreened by traditional medicinal use for anti-infectivity activity, and representing 23 genera in 19 families of 
terrestrial plants from four continents, were submitted to the NCI HIV screening program.  Of the 50 aqueous and 
solvent extracted samples, which were tested 15-30% proved weakly to strongly active against HIV in vitro. When 
these results were compared with 16,886 extracts of primary anti-HIV screens our prescreened selected samples 
proved significantly different (X2=20.9, df 1; P = 0.001).  Using aqueous and solvent extractions, noteworthy 
differences were also obtained between selected collections and random collections: 25 aqueous-extracted samples 
gave 10 active against HIV (40%) compared to NCI’s 8,443 samples and 1,174 active (13.9%) (X2 = 8.7, df 1; P = 
0.01; and 25 solvent-extracted samples gave 5 active (20%) compared to NCI’s 8,443 samples and 255 active (3%) 
(X2 = 4.9, df 1; P = 0.05). 
 For example, our studies in the Peruvian Amazon indicated that the selection of many plants used to treat 
viral hepatitis and malaria could be therapeutically verified in a number of ways. Because of confidentiality 
agreements these data will only be reported as an overview since at this time the identity of taxa or any of their 
compounds remain proprietary.  Within this context bioreactivity was not only identified by in vitro studies, but for 
hepatitis was also clinically established in the context of use (Elvin-Lewis et al., 2002).  In addition, on going 
ethnobotanical dereplications associated with these hepatitis remedies are proving to be particularly valuable in both 
identifying those taxa which are unique to a group or region but also to others, which are much more widely used for 
the same purpose elsewhere.   Many investigations identified in this latter process have also identified bioreactive 
components that are germane to their therapeutic value.     
 Also, within the context of the (International Collaborative BioDiversity Group-Peru (ICBG-Peru) Project, 91% 
(78/85) extracts from plants used to treat malaria were found active in functional tests against both chloroquine-
sensitive and chloroquine –resistant Plasmodium falciparum.  Significant activity was also elicited by a number of 
alkaloids belonging to taxa from two distinctly related families when they were tested in the P. vinckei mouse model at 
concentrations found in therapeutic formulations (Lewis et al., 2004). 
 When targeted candidates have been tested for cross-sensitivity to related organisms interesting new 
avenues of research have evolved.  This concept was first tested in preliminary studies conducted in my laboratory in 
the 1990’s utilizing secondary sources to identify some North Amerindian hepatitis remedies from our plant extract 
library.  When approximately 40% of those tested were found to inhibit HIV-reverse transcriptase activity additional 
studies were evolved using plants derived from primary data.   
 In this case, the proportion of correlative hits was significantly higher when plants were identified in the 
Peruvian Amazon from populations who participated in studies to categorize and validate the worth of viral hepatitis 
plant remedies.  Not only did many of these plants, as DMSO extracts, inhibit the processes of Hepatitis B (HBV) 
replication, but many proved to be clinically effective when validated in the context of use (Elvin-Lewis et al., 2002; 
Elvin-Lewis, 2010).  In addition, all of those that inhibited HBV replication and were submitted to NCI for HIV  
screening proved to be active to one degree or another.   Whereas some taxonomic relatedness was evident at the 
order, family or generic level (3 families, 5 genera) others proved unique.  These results were dependant upon the 
way specimens were prepared with activity being identified in 10 of 14 samples or 71.4% (7 aqueous, 3 solvent). 
Compared to the random NCI collections, this group of specific extracts was significantly different (X2 = 37.6, df 1; P = 
0.001. Following these studies, Dr. J. Cardellina, who coordinated these investigations at NCI, remarked that “he had 
never seen such a high proportion of “hits” from a group of terrestrial plant specimens”.  These initial studies indicated 
that the more valid the ethnobotanical and clinical data the more likely are plants able to be identified that possess this 
unique cross reactivity.  My recent studies into evaluating the conceptual similarities of hepatitis remedies worldwide 
are also indicating that while not all plants used in the treatment of generic and/or viral hepatitis are likely to react 
similarly, many have proven to possess comparable cross sensitivities to HIV (Elvin-Lewis, in manuscript).  Hopefully 
this potential will be assessed further, particularly in developing countries where access to conventional treatments for 
AIDS is unavailable.  
 Preliminary studies conducted under the auspices of the ICBG-Peru project have also shown that testing for 
cross-sensitivity is a valid process.  Extracts were tested by the NIAID evaluation laboratories for Cryptosporidium at 
Tufts University and for Toxoplasma at the Research institute, Palo Alto medical Foundation, headed by Saul Tzipori 
and Fausto Arauj, respectively. Seven species, shown to be active in either functional or in vivo antimalarial assays as 
described above, were tested as DMSO extracts at 0.2 μg/mL concentrations for their ability to inhibit a number of 
apicoplexan protozoa causing AIDS associated diseases.  When compared with Paromomycin at 2 mg/mL in DMSO.  
Five of these elicited inhibition of Cryptosporidium parvum at ranges comparable to, or exceeding that of Paromomycin, 
whereas the remainder was less active.  When the same extracts were studied for their ability to inhibit the RH strain of 
Toxoplasma gondii  only moderate activity was seen at 25μg/mL. In the majority of cases these activities were 
associated with some degree of host cell toxicity. Coincidental with this research were studies with 9 West African  
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 Table 1.  Index of Ethnobotanical Data Bases, URL Designations or Contact Information 
 
Category Subject URL or Web Address 
Worldwide EthnobotDB ukcrop.net/perl/ace/search/EthnobotDB 
 ETHMED http://www.toyama-mpu.ac.jp 
 HERBMED www.herbmed.org/ 
 Plants for a Future http://pfaf.org 
 SEPASAL www.rbgkew.org.uk/ceb/sepasal/ceb.html 
Regional Greater Southwest of U.S.A. www.anthro.fortlewis.edu/ethnobotany/database.htm 
 Peruvian Amazon www.biopark.org/Plants-Amazon.html 
 Prelude: Africa www.metafro.be/prelude 
 PROSEA: SE Asia www.prosea.nl 
 PROTA: Africa www.database.prota.org/ 
 South Florida, U.S.A. www.fig.cox.miami.edu/7Escofield/sofl- 
 TRAMIL: Caribbean & Latin 
America  
www.funredes.org/tramil/english/indice.html 
 WIP0: China, India, Korea www.wipo.org/ipd/en 
National  Bangladesh www.ethnobotanybd.com 
 Brazil http://www.ciagri.usp.br/planmedi/planger.htm 
 Brunei Dusan  Lucy.ukc.ac.uk/Brunei.html (Filemaker Pro download) 
 China (TCM)  cmmrc@cuhk.edu.hk 
 Hawaii www2.bishopmuseum.org/Ethnobotanydp/index 
 India –MEDFLOR (Andrha 
Pradesh) 
www.biomedexperts.com/MEDFLOR 
   NATTS cdrilk@sirnet.ernet.in 
   INMEDPLAN http://ece.iisc.ernet.in/ernet-members/frlht.html 
   AYUSH www.ccras.nic.in/ 
   TKDL  (CSIR)   http://www.indianmedicine.nic.in 
 Indonesia www.oybkuc,uastate,edy/~CYBERSTACKS/hyb-r-2htm 
 Papua New Guinea Wau Ecology Institute Herbarium  
 Madagascar www.luneroughe.org/ilerouge/produits/prod01-e.htm 
 Malta Royal University of Malta, Msida, Malta 
 Samoa www.dittmar.dusnet.de/english/ 
 Russia (FLORIN Medicinal 
Plants) 
www.florin.ru/eng 





 Turkey (FLOTURK) http://www.anadolu.edu.tr/anadolu/tbam/index.html 
Ethnic 
Groups 
Australian Aboriginal http://www.anbg.gov.au/aborig; www.scribd.com/.../CMKb; 
www.chem.mq.edu.au/~jjamie/ethnopharm.htm. 
 Canadian Gwich’in http://gwichin.ca/ 
 Maya of Central America www.ecosur.mx 
 Quijos-Quichua Shamen of 
Andes 
www.public.iastate.edu/~cbutter/ethnofra.htm 
 Native American & First 




ARICOLA (Agriculture) agricola.nal.usda.gov/ 
 Phytochemical & 
Ethnobotanical Database 
www.ars-grin.gov/duke/plants.html 
 IBIDS (Dietary Supplements) ods.od.nih.gov/health_information/ibids.aspx 




TEK*PAD  ip.aaas.org 
 
antimalarial plants. Inhibitory activity was obtained with Veronia colorata at >10g/mL, with an IC50 of 16.310g/mL  
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and its organic solvent fractions with IC50 of 1.7, 2.6 and 2.9 10g/mL for dichloromethane, acetone and ethanol 
extracts, respectively (Benoit-Vical et al, 2000).  Cross sensitivities have also been demonstrated for a Colombian 
Annonaceae species, selected for their ethnobotanical uses or chemotaxonomic relationships.  These were inhibitory 
against chloroquine sensitive and resistant strains of P. falciparum and promastigotes of three Leishmania species and 
epimastigotes of Trypanosoma cruzi (Osorio et al., 2007).   
 Ethnobotanical dereplications have also indicated the many novel compounds with the potential of being 
utilized for the treatment of tuberculosis were used to treat respiratory or other antiinfective ailments.  Unfortunately 
these structures were published before sufficient work was conducted to verify their bioreactive spectra or clinical 
potentials (Okunade and Elvin-Lewis, 2009).  
Altogether these examples indicate the value of utilizing both ethnobotanical dereplications and 
chemotaxonomic relationships for identifying new therapeutic leads. 
  Dereplication methods are useful in identifying which aspects of a pharmacopeia are unique, or known 
throughout the region as well as elsewhere.  This is an essential aspect when dealing with issues of benefit sharing 
and claims of ownership.  While initially these data might be perceived as circumscribed traditional knowledge (TK), 
additional dereplications may prove otherwise and thus designate these as regional or collective knowledge (CK).  In 
order to protect any TK during this process herbarium labels may indicate that any ethnomedical information linked to 
the specimens are only available through access to a defensive databases (Elvin-Lewis, 2006, Elvin-Lewis 2007a).   
However, when this information is already in the public domain ethnobotanical dereplications can be accomplished by 
referring to secondary data found in published material, on herbarium sheets, or part of relevant electronic journals 
and data-bases etc.  Specific data bases relevant to Ethnobotany and use of Medicinal Plants are cited in Table 1.  In 
addition, there are a number of tertiary resources, which are available only on CD-ROM or other types of offline 
electronic publications and these are listed in Table 2.  Regardless of the source it should be emphasized that there is 
likely to be a wide variation in the value of this type of information with more credence given to those data, which have 
been scientifically validated and published in peer reviewed journals. 
 Numerous databases associated with the use and value of medicinal plants can be elicited through referring 
to lists provided by the Alternative Medicine Resources at http://www.pitt.edu/~cbw/database.html. as well as others 
cited by Thomas (2003).The current Medicinal Plant Database of K.K. Bhat (http://joyppkau.tripod.com/-
WordFiles/MP.doc) provides considerable detail concerning the nature of these sites. Several additional databases 
associated with Complementary and Alternative Medicine (CAM) can be found by eliciting 
http://www.rosenthal.his.columbia.edu/Databases.html. or others cited by Wooten (1997) and Allias et al. (2000). 
 Of significant value are those databases that include sources acquired world wide, such as the United 
Kingdom’s, EthnobotDb, and SEPASAL(Survey of Economic Plants for Arid and Semi-Arid Lands) maintained by the 
Royal Botanic Gardens, Kew.  The latter is limited to those plants growing in dry tropical and subtropical climates. 
Also useful for medicinal foods is the British, Plants for a Future database. An excellent resource for scientific studies 
related to medicinal herbs is the American-based website HerbMed® developed by the Alternative Medicine 
Foundation. Under development is the Japanese database, ETHMED, which is being compiled at the Takko Kaiseki 
Center (Analytical Research Center for Ethnomedicine) and the Institute of Wakan-Yaku (Traditional Sino Japanese 
Medicines) associated with Toyama University.  This project involves providing comprehensive biological, chemical 
and taxonomic data based on their world wide medicinal plant herbarium collections and the 20,000 crude “drug” 
samples held at the Museum Materia Medica of the Institute. 
 
Table 2:  For Fee, Membership, eBooks and CD Rom Format Databases: Alternative Medicine, Medicinal Plants   
Category Organization Address: URL, Web Address or CD-ROM 
Africa AHA https://apps.who.int/hlt/otherdata/English/african.htm; CD-
ROM 
Asia-Pacific AHEAD 3 disc CD-ROM 






CD-R0M and Electronic Books 
France PASCAL http://www.inist.fr 
 PLANTES MEDICINALES CD-ROM 
Korea TRADIMED CD-ROM 
United Kingdom CABI Medicinal Plant www.cabi.org 
 Hom-Inform hominform.soutron.com/ 
 GREEN MEDICINE 
(Chinese Herbal Medicine) 
Hopkins Technology CD-ROM 
U.S.A. HerbMedProTM www.herbmed.org/members/ 
 Biosis Previews  http://www.biosis.org and CD-ROM 
 MANTIS www.healthindex.com/ 
 HERBALIST http://www.hoptechno.com/ and CD-ROM 
 TCM & Pharmacology http://www.hoptechno.com/ and CD-ROM 
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Other comprehensive databases of specific regions, countries or populations may represent general compellations of 
an individual, specific group or organization.  Their usefulness is variable because of the quality and quantity of data 
presented.  Utilization of these may be free or require a fee or membership to an organization. 
  Regionally based databases include those assembled from the traditional medicinal systems of Asia as 
generated by World Intellectual Property Organization (WIPO) member states of China, India and Korea. PROSEA 
(Plant Resources of South-East Asia) is a collaborative effort of participating organizations in Indonesia, Malaysia, 
Papua New Guinea, Phillipines, Thailand, VietNam with publishing offices in Wageningen, Netherlands). For Africa, 
Prelude Medicinal Base of African ethnobotany and ethnomedicine encompasses information used by humans and for 
veterinarian purposes gleaned from the colonial period until today. These data are correlated with current information 
related to taxonomic and biomedical research. PROTA, available in either English or French is another database, 
which identifies useful plants of tropical Africa. Medicinal plants of the Caribbean and Latin America can be found in 
TRAMIL which has generated an ebook on the Caribbean pharmacopeia in addition to a CD-ROM on conservation.  
Some databases attributed to uses in the Peruvian Amazon, the greater southwest and South Florida of the U.S. may 
be limited in scope. 
 Those of national origin include Bangladesh, Brazil, Brunei, China (Chinese Medicinal Material Research 
Center (CMMRC), India (MEDFLOR, NATTS, INMEDPLAN,AYUSH,TKDL), Hawaii, Indonesia, Papua New Guinea, 
Madagascar, Malta, Samoa, Russia (Florin Medicinal Plants), Spain, Thailand, Tibet and Turkey (FLOTURK).   
 Additional sources may be restricted to circumscribed groups such as the Gwich’in of Northern Canada, the 
Aboriginal people of Australia, Maya of Central America, the Quijos of the Andes, or those in India that practice 
specialized medicinal systems such as Aryurveda (Unnikrishnan, 2005) or AYUSH (Aryurveda, Yoga, Unani, 
Naturopathy, Siddha and Homeopathy).  Alternately, the Native American Ethnobotany Database describes uses of 
indigenous Amerindian tribes/1st Nations in both the U.S. and Canada, respectively. 
 Noteworthy among the free databases generated by the U.S. government is one for agriculture called 
ARICOLA with over 3 million records of post 1970 publications and those found in the Phytochemical and 
Ethnobotanical databases compiled by J. Duke. Others related to medicinal plants such as The International 
Bibliographic Information on Dietary Supplements (IBIDS) (a PubMed dietary supplement subset), the U.S. Patent 
and Trade Office (USPTO).  Additional American private or institution generated databases include HerbMedTM , the 
online Archive of American Folk Medicine and the Traditional Ecological Knowledge Prior Art Database (TEK*PAD) 
concerning indigenous knowledge and plant uses, which is  maintained by the American Association for the 
Advancement of Science.  
 Specialized for fee databases include in the U.S. Biosis Previews, which is considered the world’s largest 
database on medical and biological subjects with over 12 million citations. Access is available on line or through CD-
ROM distributors. In addition membership fees to the American Botanical Council are required to elicit 
HerbMedProTM,a more professional version of HerbMed® . This is an interactive herbal database developed by the 
Alternative Medicine Foundation linking scientific evidence underlying the use of herbs for health. Another fee based 
database is called MANTIS (Manual, Alternative and Natural Therapy Index), which utilizes ChiroACCESS;( the online 
Chiropractic community), Dialog Corporation, Health Index and OVID Technologies, Inc. Currently it cites about 
417,000 references obtained from over a thousand, mostly peer reviewed journals. 
 United Kingdom-based for fee databases include the CABI Medicinal Plant Database, which comprises 
aspects of human health and nutrition, the Hom-Inform Database produced by the British Homeoepathic Library at 
Glasgow Homoepathic Hospital and the Society of Homeopaths, Treuherz Collection, and the Index to Chiropractic 
Literature.  In France, the large multilingual bibliographic data base, PASCAL compiled by the Institute de 
l’Information Scientifique et Technique (INIST) can be accessed both online and offline and cites over 500,000 
records in science and technology.  
 Regional for fee or membership databases, may also be for sale in a CD- ROM format.  In Asia, these 
include the Korean and Chinese TradiMed, The Chinese TCM Database and Chinese Materia Medica, the Japanese 
JICSR-EPlus, and FRLHT (Bio-informatics on Medicinal Plants and Traditional Knowledge) based in India. The latter 
is a compilation of 7,500 botanical names associated with local traditional uses. The UNESCO-sponsored project, The 
Asian Pacific Information Network on Medicinal and Aromatic Plants (APINMAP) is a consortium of countries 
(Australia, People’s Republic of China, India, Indonesia, Republic of Korea, Malaysia, Nepal, Pakistan, Papua New 
guinea, the Philippines, Sri Lanka, Thailand, Turkey and Vietnam) with a Secretariat based in the Philippines.  Its 
database contains bibliographic and factual information on medicinal plants in addition to contact information and the 
activities of member scientists conducting research in this discipline.  Another Asian collaborative effort called the 
Asian Health, Environmental and Allied Databases (AHEAD) between India, Thailand, Philippines, Malaysia, 
Singapore and Bangladesh is sponsored by the International Development Research Center of Canada.  Coordinated 
in New Delhi by the National Institute of Science Communication (NISCOM) a 3 disc CD-ROM series has been 
developed on the Environment, Health and Wealth of Asia. Incorporated into the latter disc is the entire Medicinal and 
Aromatic Plants bibliographic database in addition to the plant and mineral resources listed in the Wealth of India.  
The African Health Anthology, produced by the National Information Services Corporation (NISC) South 
Africa, represents a compilation of comprehensive databases related to African health issues from 1924 to the 
present, including those related to alternative and complementary medicine.  Traditional Medicinal Plants of the 
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Caribbean and Latin America (TRAMIL) is an interdisciplinary collaboration of Caribbean institutions to study their 
traditional popular medicines.  Within this context they have published in electronic book form both English and 
Spanish versions of the Caribbean Herbal Pharmacopeia 2nd Ed (Germosén-Robineau, 2006) in addition to a booklet 
Plantas Medicinales Caribeñas para la Atención Primaria (Cuba) and a CD-ROM on conservation.  Two multimedia 
CD-ROMs are available from Hopkins Technology of Hopkins, Minnesota. The Herbalist by David Hoffman is an 
encyclopedia of western herbal medicine and cites the uses of 170 plant species and the Traditional Chinese 
Medicine and Pharmacology describes the use of 322 medicinal herbs. 
 Access to medicinal traditional knowledge in other countries will depend if these have been evolved from 
secondary information or as primary data are placed into defensive databases with for fee and restricted access as is 
the BioZulua of Venezuela (Elvin-Lewis 2006, Elvin-Lewis, 2007a).  Whatever the source, utilizing these whenever 
possible and practical is invaluable to understanding the relative value of a particular ethnic group’s medicinal plant 




 Most countries with national herbaria are useful reference sources for information regarding the nature and 
distribution of taxa within a nation and adjacent territories.  Moreover large herbaria with collections ranging from 
about 5-9 million collections are likely to have comprehensive representations from around the world and especially 
from countries where their interests are now presently, or have been in the past.  These include in order of the 
number of specimens in their collections the Muséum National d'Histoire Naturelle (P), Paris;  Royal Botanic Gardens, 
Kew (K), London, England; New York Botanical Garden (NY), New York, USA , the Komarov Herbarium  (LE), St. 
Petersburg, Russia Conservatoire et Jardin botaniques de la Ville de Genève (G), Geneva Switzerland, The Nationaal 
Herbarium Nederland (NHN)(L, U, WAG); The National History Museum formerly The British Museum of Natural 
History (BM); London, England the Missouri Botanical Garden (MO) St Louis MO, USA, and Harvard University 
Herbaria (GH,A, AMES,ECON,FH), Cambridge Mass, USA.  In addition, the United States National Herbarium (BCI) 
at the Smithsonian National Museum of Natural History (DC) with its 4.5 million specimens is particularly rich in type 
specimens (90,000). These institutions are also likely to have specialist botanists that can aid in the determination of 
difficult to identify or unknown taxa.   Reference to their collections and current taxonomic determinations of this 
material can be made by accessing their websites in Table 3.   
 Reference to the International Plant Names Index (www.ipni.org/) would also be helpful.   Access to the 
professional botanical literature for additional check lists, floras, and monographs etc. is also valuable for 
understanding what is known botanically regarding the species in question, if they are taxonomically defined, and 
which taxa are more closely allied to them.  Another important resource for ethnobotanical and ethnomedical 
information are citations on herbarium labels, albeit often annotated by individuals of limited medical knowledge. 
 
Table 3: Website/URL Addresses of Botanical Institutions 
Institution Web Address /URL  
Conservatoire et Jardin 





asaweb.huh.harvard.edu:8080/databases/specimen_index.html).   
 













NY Botanic Garden’s 
C.V. Starr Virtual 
Herbarium 
www.nybg.org/bsci/hcol 
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 Prior to the development of medical and biological library search engines in the 1950’s these types of studies 
were particularly time consuming and depended on the library acquisitions available to the investigator.  While clearly 
biomedical research has evolved since then, these older acquisitions are still an invaluable resource for those wishing 
to identify the basis for some studies that are now being conducted.  A useful way to identify these types of relevant 
references is to look at current publications for these types of early citations. Be aware that the titles themselves may 
be misleading as to the types of plants or plant parts that have been studied or the nature of bioassays that have been 
applied.   
 Today a number of major biomedical bibliographic databases exist that are invaluable to the biomedical 
investigator (Table 4).  Of these, Pub Med of the National Library of Medicine (NLM), USA is perhaps the most 
utilized, since it is free and available by public web access.  Going back to 1950, the database contains over 15 
million references from 5,000 journals in 37 languages. Keywords are indexed as MeSH terms. Also the official 
publication of Pharmacognosy network provides free access to Caspur, DOAJ, EBSCO Publishing’s Electronic 
Databases, Excerpta Medica / EMBASE, Google Scholar, Index Copernicus, OpenJGate, PrimoCentral, ProQuest, 
SCOLOAR, SCOPUS, SIIC databases, Summon by Serial Solutions, and Ulrich’s International Periodical Directory.  
Also a free ebook pdf of Pharmacognosy theses is useful in finding unpublished information on these subjects. 
 Several subscription-based, for fee online databases also exist, for example,  Embase produced by Elsevier 
Science BV of the Netherlands incorporates extensive data on both pharmacological as well as biomedical and drug 
research and also allows access to selected MEDLINE records.  The Qigong Database provides 2,050 citations on 
various aspects of clinical and experimental research. Also within this category is the relational database, NAtural 
PRoducts ALERT (NAPRALERT), which is described in full under the section on Chemistry. 
 
 
Table 4:  Major Website/URL Addresses on Biomedical/Pharmacognosy Subjects 
 
Type Web Address or URL 
PubMed www.ncbi.nlm.nih.gov/pmc/ 
Pharmacognosy network  www.phcogres.com 
Unpublished theses and dissertations on 
pharmacognosy 
www.ebookpdf.net/database-of-pharmacognosy-






Table 5:  Free Major URL or Website Addresses of Clinical Studies 
 
Type Web Address or URL 
CUGH www.cugh.org/ 
CenterWatch www.centerwatch.com 
Cochran Collaboration Cochran.org 
Cochran CAM Field www.compmed.umm.edu/cochrane_about.asp 
U.S. Government  clinicaltrials.gov/ 
    CAM www.cam.nih.gov/research/clinicaltrials/factsheet/clinicaltrials.pdf 
 
    CRISP http://report.nih.gov/crisp/ 
    NLM www.nlm.nih.gov/news/expanded_clinicaltrials.html 
 FDA Poisonous          Plant Database www.accessdata.fda.gov/scripts/plantox/index.cfm 













 Information regarding relevant clinical studies can be elicited by accessing either free (Table 5) and “for fee” 
databases (Table 6). For individuals wishing to determine the global or regional distribution of specific diseases, 
referral to national Communicable Disease Centers and/or the World Health Organization websites are reliable 
resources.  Regional medical centers and/or national medical schools are likely to be helpful as are certain University 
Medical Schools or Institutes with interests in global medicine such as those, which are apart of the Consortium of 
Universities for Global Health (CUGH). 
 Free databases describing clinical trials include the global CenterWatch which is categorized according to 
therapeutic and geographic regions and reports ongoing industry and government-sponsored studies.  In the U.S. the 
Cochrane Collaboration, and the Cochrane CAM Field maintains and updates a registry of randomized controlled 
trials; US government-based databases include the Complementary and Alternative Medicine (CAM) and the National 
Institute of Health’s, NLM Databases accessed through PubMed, ClinicalTrials.gov, and CRISP (Computer Retrieval 
of Information on Scientific Projects) describing the National Institutes of Health (NIH) sponsored biomedical research 
on natural medicine, herbal medicines, and dietary supplements and the Poisonous Plant Database of the U.S. Food 
and Drug Administration (FDA). In the United Kingdom, Bandolier is a tertiary compilation of evidence-based 
database describing published research and clinical trails on specific treatments whereas the CISCOM Database (The 
Centralized Information Service for Complementary Medicine) represents a large database regarding complementary 
therapies and clinical trials. In Germany, the holistic medicine database, DATADIWAN (Pattienteninformation fur 
Naturheilkunde: Patient information for natural therapies) links research institutions and organizations worldwide with 
over 6,000 bibliographic entries and addresses.  
 The for-fee database, AMED (Allied and Complementary Medicine Database) is produced by the British 
Library Health Care Information Service and contains primarily European references including many not found in 
MEDLINE or EMBASE. For fee access is also required for The Natural Standard, which is a global collaborative 
endeavor highlighting evidence-based, consensus-based, and peer-reviewed data on herbal medicine, supplements, 
conditions and alternative modalities. An interactive database on the Poisonous plants in Britain and Ireland is 
available in CD-ROM form.  
 Additional alternative medicine resources which are likely to illustrate the therapeutic value of medicinal 
plants include ACUBASE by the Bibliothèque Universitatire de Médicine de Nîmes with over 17,000 French and 
English references, including conference proceedings on acupuncture and Traditional Chinese Medicine (TCM), 
AltHealthWatch of EBSCO Information Services.  
 
Chemical Dereplication and Patent Databases  
 
 Within the context of utilizing chemical dereplication it is essential to understand that a herbal remedy may 
consist of plants containing one or more compounds with complementary or different activities or a group of plants 
taken together (polyherbal) or sequentially to optimize the effects of the treatment.  Variances in the chemical 
composition of each plant can depend upon the climate and soil compositions in which it was grown, the season in 
which it was harvested, the method of harvest and preparation, as well as how it was stored and prepared.  Moreover 
within the range of its distribution one species may be represented by a number of chemotypes, which can vary in the 
proportion of bioreactive component/s such as the fraction of bioreactive to non reactive isomers they might contain.  
Obviously these inconsistencies would be directly related to how these chemotypes are valued in a particular region.  
Chemical analysis is apt to yield a number of bioreactive ubiquitous compounds along with others that are unique to 
the species or shared among closely allied species or genera. Understanding these possibilities is useful in identifying 
particular taxa that may have greater therapeutic potential or others that serve sourcing needs. 
 On the whole most medicinal plants, in the context of traditional use, are valued because they are moderate 
in potency and toxicity.  When toxicities are known, parameters of use, including the nature of the formulations are 
often carefully delineated to avoid any problematical outcome elicited by over-dosage.  Usually these medications are 
taken for circumscribed short periods of time to treat acute illnesses rather than for prolonged periods needed for 
chronic conditions. They rarely meet the criteria for pharmaceutical development because their bioreactive 
compounds are likely to be structurally complex containing numerous chiral centers in addition to representing 
mixtures of active and non reactive isomers. It is commonplace for one plant to contain a number of related 
compounds, which can synergistically or in complementary ways elicit the optimal therapeutic goal.  Within the 
commercial arena of Western herbal medicine these medicinal plants are sometimes standardized by the chemical 
“fingerprinting” of their bioreactive ingredients into reliable phytopharmaceuticals.   Only rarely is a candidate identified 
with pharmaceutical potential such as being highly potent, low in toxicity and molecular weight, structurally simple, 
user friendly, and if necessary readily semi-synthesizable to enhance its therapeutic value.  Of course if development 
is to go forward, issues of availability must be rationally addressed such as identifying practical ways for resource 
management of the species itself, or identifying others with the same compound that are more easily grown or with 
precursor molecules that through semi-synthesis can provide the active molecule. Ideally, the pharmaceutical industry 
prefers those compounds that can be practically synthesized, since this method overcomes issues related to utilizing 
the natural resource. Another alternative method is related to the discovery that many compounds are the result of 
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endophytic (systemic fungal) infections e.g., paclitaxel (Lewis and Elvin-Lewis, 2003). This aspect continues to be 
explored to ensure that bioculture can provide yields of a particular compound sufficient enough to be usefully applied.  
 A number of other strategies have also been proposed to achieve these goals.  These not only utilize 
biodiversity to identify new chemical entities but are also associated with identifying additional disease-associated 
molecular targets so that new treatments can be realized. One useful review paper (Basso et al., 2005) describes 
mechanistic-based strategies to identify natural compounds from ethnobotanical and chemotaxonomic studies, which 
may have therapeutic potential in the treatment of malaria, tuberculosis, and chronic degenerative diseases. The 
authors’ primary criteria for selecting natural products over those evolved through combinatorial chemistry, is because 
their structural diversity is more likely to identify biologically active compounds by interacting with a wide variety of 
proteins and biological targets. Unlike their synthetic or combinatorial counterparts they are represented by a broader 
distribution of molecular properties, which includes molecular size, octanol-water partition coefficients, and diversity of 
ring systems.  This broad screening approach, which is considered cost effective, describes the evaluation of plant 
extracts as well as pure substances for their ability to inhibit targeted mechanisms such as pathway enzymes so as to 
identify those with selective toxicities related to their specific chemotherapeutic potential.  Expanding on this concept 
is what is referred to as “reverse pharmacognosy” (from diverse molecules to plants) coupled with pharmacognosy 
(from biodiverse plants to molecules), which combines the use of high throughput screening, virtual screening and 
knowledge databases associated with the traditional uses of plants (Do and Bernard, 2004; Blandeau et al., 2010).  
 The use of a number of chemical databases dealing with pharmacognosy and natural product’s chemistry 
are invaluable in understanding the therapeutic bases for any pharmacopeia (Corley and Durley, 1994). Reference to 
these should provide information substantiating the nature of phytochemicals of interest or others related to them. 
Additional studies associated with the basis of their bioreactivies toxicological profiles, or other medicinal parameters 
of worth are also likely to become evident.  
 In order to facilitate the rapid characterization of known compounds, chemical dereplications have become 
an important asset.  To expedite the process these databases may be available for non commercial purposes in an 
open access format, or may require permission or use for a fee from the provider should they be used for commercial 
purposes.  This is true of the SuperNatural database (generated by the Oxford University Press, which requires 
permission and/subscription from industry. Among these is a recently developed database for the dereplication of 
natural product mixtures in bioassay-guided protocols called NAPROC-13.  Through analysis of over 6000 natural 
products, structural information associated with chemical substructures, spectral features, chemical shifts and 
multiplicities are provided. Also accessed according to the standard classification of natural compounds are searches 
for trivial and semi-systematic names, molecular forms, families, types and groups of compounds (López-Perez et al., 
2007).  
 Other “for fee” databases can be accessed by academic researchers through institutional subscription.   
Among these is ChemnetBase representing a comprehensive structure database whereby one can elicit  online 
versions of the Handbook of Chemistry and Physics, Polymers: a Property Database, Properties of Organic 
Compounds, Combined Chemical Dictionary, in addition to a number of subject-based Dictionaries for organic 
compounds, drugs, inorganic and organometallic compounds, commonly cited compounds, marine natural products, 
food compounds, carbohydrates, and natural products. Also accessed through this search engine is The Chapman 
and Hall/CRC database, which was once available in hard copy or in CD-ROM and is now updated every six months 
in its online version.   
 Chemical Abstracts markets a number of relevant databases including Scifinder Scholar, which focuses on 
current chemical and related biological research as well as patents and patent applications.  Included within this 
database are numerous patent applications, which have not received full patent status. These usually represent 
polyherbal formulae from Asian countries.  The data that are provided are nonetheless useful in identifying ways in 
which medicinal plants, their compounds and derivatives are being promoted.  Reference to the collection of 180 
databases found in the Scientific and Technical Network International (STN) provides for the rapid characterization of 
known compounds such as their formula weight, carbon count, structure fragments, bioactivity and taxonomy. Of 
these CA, REGISTRY, BEILSTEIN, SPECINFO, MEDLINE, EMBASE, JICST, and BIOSIS and NAPRALERT are 
most often used by natural products chemists.  The latter, is a relational database from the University of Illinois, which 
surveys the worldwide literature on natural products and secondary metabolites and includes ethnomedical, 
pharmacological/biochemical, clinical studies and plant distribution studies. Its over 200,000 records encompass data 
from 1650 to the present, with more comprehensive coverage found between the years 1975-2003. Linked to this is 
DEREP (DEREPlication) which contains data on the physical constants of natural products.  Additional Natural 
Products databases include Berdy’s antibiotic database known as the Bioreactive Natural Products Database (BNPD) 
developed in collaboration with the U.S. National Cancer Institute. Additional for fee databases relevant to chemistry 
can be accessed by referring to Chemistry and Engineering Databases through Universities or similar institutions that 
subscribe to these products.  
 Throughout the nations of the world there are variances on how patent law can be applied to the utilization of 
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Table 6:  URL or Website Addresses of Clinical Studies: Fee or CD-ROM 
 




Natural Standard  www.naturalstandard.com/ 
Poisonous Plants in Britain and Ireland (CD-ROM) http://194.128.652/publicat/titles/plants/plants.htm 
 
 
Table 7: Chemical Dereplication and Patent Databases 
 
Type URL or Website Address 
SuperNatural  http://bioinformatics.charite.de/supernatural 
journal.permissions@oxfordjournals.org 
Chapman and Hall/CRC  library.dialog.com/bluesheets/html/bl0303.html 
ChemnetBase www.chmnetbase.com 
STN  www.stn-international.de/database.html?&tx ptgsashop 
BNPD www.bio.net/mm/bio-www/1998-January/000703.html 






it is possible to identify relevant plant derived compounds or their derivatives from numerous global, regional or 
national Patent Databases (wiki.piug.org ) (Table 7).  Of these the World Intellectual Property (WIPO) database 
referred to as WIPO GOLD provides access to online intellectual property databases hosted by WIPO and member 
states.  Free access is possible to The Canadian Patent Database, The State Intellectual Property Office of the 
People’s Republic of China, the European Patent Organization, and The United States Patent and Trademark Office 
Patent Database.  For Western and South East Asian Countries access to patents in the natural medicine/traditional 
field are identified through The World Traditional/Natural Medicine Patent Database. Currently it represents over 
400,000 documents, which can be elicited by classification and keyword, full texts are unavailable. It also supports a 
chemical structure query interface as well as a Chinese medicine formula similarity search.  Also available is the” for 






 Suitable dereplications are useful in validating pharmacopeias in many ways. Numerous databases have 
been evolved to aid in these endeavors and should be employed in addition to other sources whenever possible.  
Without these references the worth of ethnobotanical data related to medicinal uses is limited at best.   
 For example, it is only human nature for those that still utilize and value their medicinal plants to believe that 
its content is uniquely circumscribed.  It is therefore important that before initiating medicinal plant inventories, when 
prior informed consent is elicited, that those who are custodians of this traditional knowledge and the informants they 
designate are aware that the process will include differentiating those aspects that are novel from those that are not. 
This should mollify any unrealistic expectations of worth, since clearly exclusive information is likely to have greater 
value to them than others known generally.   
 From the onset it is critical to emphasize how these data will be managed during the verification process and 
which aspects are expected to benefit them directly. Clearly botanical dereplications are required to accurately access 
the identity of any medicinal plant and its relationship to other taxa that might be known regionally.  By using 
ethnobotanical dereplications the exclusivity of certain plant remedies are likely to become evident, as are those that 
are more widely valued.  
 Understanding the spectrum of these uses is also helpful to those wishing to investigate the mechanistic and 
chemical basis of these remedies.  If optimal results are to be achieved the application of disease-targeted assays is 
preferred, since these can also be used in biodirected isolations of the active compounds. Clearly the value of these 
results can be amplified if related plants or target diseases are tested to identify additional potential uses. Reference 
to the myriad of databases on these subjects is not only important in selecting the appropriate assay tools, but also in 
understanding the therapeutic role of  compounds already isolated from related taxa. Evaluating certain remedies in 
the context of use is only justified once a critical need has been identified to warrant the expenditure of time and 
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treasure.  In addition to the utilization from basic science databases, reference to those describing relevant clinical 
studies or patents is worthwhile.  
 Overall it is important to emphasize that it would be a rare event to identify from ethnobotanical sources 
potential pharmaceutical compounds, which are novel, potent and safe.  More than not, most plant remedies contain 
compounds that are moderate in efficacy and toxicity, and are too complex or ubiquitous to be categorized in this 
manner.  However, there are some plants or plant mixtures which merit consideration for use as botanicals or 
phytopharmaceuticals.  It is these approaches that are more likely to be pursued once basic studies have been 
completed in evaluating an indigenous pharmacopeia.  It is within this context that reference to known information is 
so very relevant and where benefit -sharing with those that are custodians of the original traditional knowledge are 
more likely to be achieved.  
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